Antares submits new drug application to FDA for Quickshot Testosterone
Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Essential IR Insights Newsletter - February 2023
Antares Pharma Inc. submitted a new drug application to the U.S. FDA for its QuickShot Testosterone, a drug-device combination product for treating men with low testosterone associated with hypogonadism.
The product delivers testosterone enanthate using a subcutaneous auto injector.
